Add like
Add dislike
Add to saved papers

Asymmetric tetranuclear nickel chains with unidirectionally ordered 2-(α-(5-phenyl)pyridylamino)-1,8-naphthyridine ligands.

The new ligand, 2-(α-(5-phenyl)pyridylamino)-1,8-naphthyridine (Hphpyany), was synthesised by a palladium(0)-catalysed reaction of 2-chloro-1,8-naphthyridine with 2-amino-5-phenylpyridine in the presence of potassium tert-butoxide. Linear tetranickel metal complexes, [Ni4 (phpyany)4 Cl2 ](CF3 SO3 ) 1, [Ni4 (phpyany)4 Cl2 ](BF4 )2 2, [Ni4 (phpyany)4 (NCS)2 ](ClO4 ) 3 and [Ni4 (phpyany)4 (NCS)2 ](CF3 SO3 )2 4 were prepared and crystallographically characterised. Complexes 1-4 demonstrate that, for the first time, four asymmetric ligands align unidirectionally and thus configure (4,0)-form tetranickel strings, specifically, with the phenyl groups of the four phpyany- pointing to one side of the Ni4 chain and naphthyridyl to the other. The remarkably short Ni-Ni distances (ca. 2.33 Å) for 1 and 3 indicate partial metal-metal bonding, which can be viewed as both complexes containing one mixed-valence Ni2 3+ unit. The measurements of the magnetic susceptibility reveal that Ni4 7+ complexes 1 and 3 exhibit antiferromagnetic interactions (J = -42 cm-1 for 1 and -46 cm-1 for 3) between the terminal Ni2+ ion and the Ni2 3+ unit, while Ni4 8+ complexes 2 and 4 exhibit antiferromagnetic interactions (J = -33 cm-1 for 2 and -35 cm-1 for 4) between the two terminal Ni2+ ions. The results of the cyclic voltammetry indicate the presence of two reversible redox couples at E1/2 (1) = 0.12 V, E1/2 (2) = -0.65 V for 1, and at E1/2 (1) = 0.12 V, E1/2 (2) = -0.72 V for 3. The products of the first oxidation for 1 and 3 are the oxidised species 2 and 4, respectively. The values of single-molecule resistance (15.4 (±3.46) MΩ for 3 and 16.2 (±5.04) MΩ for 4) were determined by STM-based break-junction methods. The results represent the first conductance measurements of linear tetranickel chains.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app